Should you invest in... the biotech business?

IF YOU are an investor looking for a "frontier market", you do not have to stray far from home. For those research-based companies at the cutting edge of technological development will give you a rollercoaster ride for your money every bit as exciting, and fraught with risk, as any emerging market.

Chief among these high- risk enterprises are the biotechnology stocks, those companies whose raison d'etre is to develop new products and processes through biochemical research and whose success or failure is often dependent upon their ability to develop and market a single new drug.

"There are very few biotech stocks that we look at, because the companies are so tiny and it has been an awful subsector to be in," says Jeremy Batstone of NatWest Stockbrokers. "It is an unloved sector which has seen a lot of disappointments, the most high profile of which was British Biotech."

In contrast to the outperformance of their bigger counterparts in the pharmaceutical companies, the small biotech sector has been suffering. Mark Mathias, marketing director of Finsbury Asset management,says: "Biotech shares have been complete dogs for two years. There have been some celebrated cases of bad management, which led to a bad press for the sector, which has depressed sentiment."

Glenn Meyer of Pavilion Asset Management says: "You have to adopt a portfolio approach to the biotech sector. Investing in individual biotech companies should be left to the specialists."

Lesley Buckett of Hill Samuel Asset Management says: "They are mainly very small cap stocks. The private investor would have to buy a lot of them to make an impact and the best way would be to have a portfolio via something like an investment trust. People who specialise in looking only at these stocks get it wrong, so what chance does the individual have? You are dealing with `blue sky' research, and how do you know that these scientists are actually going to come up with anything?"

Jeremy Batstone adds: "The trouble with biotech stocks is that they have had their glory days. Two or three years ago, when British Biotech's `wonder drug' was starting trials, these stocks were racing away and standing on ridiculous multiples. But as they have no earnings you can't properly rate companies like that - British Biotech was almost in the FTSE 100 at one point and hadn't actually produced anything. Now you can really see the wood for the trees and there isn't much of either."

Lesley Buckett says: "Biotech stocks were very lowly rated, then got very highly rated very quickly, as things like British Biotech began to take off. The pharmaceutical sector is a large part of the market, but that is on the basis of three very large stocks. The biotech companies have become even smaller with the derating they have experienced over the past couple of years."

Much of the problems associated with the sector have stemmed from long lead time. Mark Mathias says: "The underlying businesses take cash at the outset, then there is a long period when nothing seems to be happening because they are in the laboratory coming up with the drugs. So there was no news coming out of the biotechs, then bad news because of British Biotech and other bad management situations. Now positive news is coming through."

Jeremy Batstone says: "A company will build up market expectation of finding a cure for cancer or whatever, then let you down in a big way when you find it doesn't work. It means taking giant leaps of faith." Lesley Buckett says: "Ratings have become more sensible and you are beginning to see the same sort of cycle you see in the US. But these companies burn cash at an enormous rate. They will all need refinancing at some point."

When it does work, the rewards can be enormous and the best evidence comes from America. Mathias adds: "Biotech companies make profits by doing deals. There are 21 biotech companies in the US representing a total of $1.5bn (pounds 940m) in profits and this figures is going to rise to $2.5bn by the end of 2000. And they are available on an average p/e of 25 times earnings, which is reasonable.Some companies, like Powderject Pharmaceuticals, have developed world-leading technologies, although in this case it is a delivery system rather than an actual drug. SkyePharma is a company with successful technology, as is Chiroscience."

Jeremy Batstone says: "You have to consider how they are going to sell these drugs. Have they got marketing power? Chiroscience had a deal with Zeneca to market a drug, then after the Zeneca-Astra dealChiroscience was out in the cold, because Astra had a similar drug and didn't want a third party involved."

Arts and Entertainment
Gregg Wallace in Summer's Supermarket Secrets
tv All of this year's 15 contestants have now been named
Sport
The giant banner displayed by Legia Warsaw supporters last night
football Polish side was ejected from Champions League
Arts and Entertainment
Could we see Iain back in the Bake Off tent next week?
tv Contestant teased Newsnight viewers on potential reappearance
News
i100(and it's got nothing to do with the Great British Bake Off)
PROMOTED VIDEO
News
news It's not just the world that's a mess at the moment...
News
Angelina Jolie with her father Jon Voight
peopleAsked whether he was upset not to be invited, he responded by saying he was busy with the Emmy Awards
News
Bill Kerr has died aged 92
peopleBill Kerr appeared in Hancock’s Half Hour and later worked alongside Spike Milligan and Peter Sellers
Life and Style
A picture taken on January 12, 2011 shows sex shops at the Paris district of Pigalle.
news
Sport
footballPremiership preview: All the talking points ahead of this weekend's matches
News
Keira Knightley poses topless for a special September The Photographer's issue of Interview Magazine, out now
people
News
ebooksAn evocation of the conflict through the eyes of those who lived through it
Voices
The Ukip leader has consistently refused to be drawn on where he would mount an attempt to secure a parliamentary seat
voicesNigel Farage: Those who predicted we would lose momentum heading into the 2015 election are going to have to think again
Arts and Entertainment
Cara Delevingne made her acting debut in Anna Karenina in 2012
film Cara Delevingne 'in talks' to star in Zoolander sequel
News
i100
Sport
Mario Balotelli pictured in his Liverpool shirt for the first time
football
Life and Style
tech
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Data Scientist (SQL,Data mining, data modelling, PHD, AI)

£50000 - £80000 per annum + benefits+bonus+package: Harrington Starr: Data Sci...

SAS Business Analyst - Credit Risk - Retail Banking

£450 - £500 per day: Orgtel: SAS Business Analyst, London, Banking, Credit Ris...

Project Manager - Pensions

£32000 - £38000 Per Annum Bonus, Life Insurance + Other Benefits: Clearwater P...

KYC Analyst, Birmingham - £200-£250 p/d

£200 - £250 per day + competitive: Orgtel: KYC Analyst, Key Banking Client, Bi...

Day In a Page

Ukraine crisis: The phoney war is over as Russian troops and armour pour across the border

The phoney war is over

Russian troops and armour pour into Ukraine
Potatoes could be off the menu as crop pests threaten UK

Potatoes could be off the menu as crop pests threaten UK

The world’s entire food system is under attack - and Britain is most at risk, according to a new study
Gangnam smile: why the Chinese are flocking to South Korea to buy a new face

Gangnam smile: why the Chinese are flocking to South Korea to buy a new face

Seoul's plastic surgery industry is booming thanks to the popularity of the K-Pop look
From Mozart to Orson Welles: Creative geniuses who peaked too soon

Creative geniuses who peaked too soon

After the death of Sandy Wilson, 90, who wrote his only hit musical in his twenties, John Walsh wonders what it's like to peak too soon and go on to live a life more ordinary
Caught in the crossfire of a cyber Cold War

Caught in the crossfire of a cyber Cold War

Fears are mounting that Vladimir Putin has instructed hackers to target banks like JP Morgan
Salomé's feminine wiles have inspired writers, painters and musicians for 2,000 years

Salomé: A head for seduction

Salomé's feminine wiles have inspired writers, painters and musicians for 2,000 years. Now audiences can meet the Biblical femme fatale in two new stage and screen projects
From Bram Stoker to Stanley Kubrick, the British Library's latest exhibition celebrates all things Gothic

British Library celebrates all things Gothic

Forthcoming exhibition Terror and Wonder: The Gothic Imagination will be the UK's largest ever celebration of Gothic literature
The Hard Rock Café's owners are embroiled in a bitter legal dispute - but is the restaurant chain worth fighting for?

Is the Hard Rock Café worth fighting for?

The restaurant chain's owners are currently embroiled in a bitter legal dispute
Caribbean cuisine is becoming increasingly popular in the UK ... and there's more to it than jerk chicken at carnival

In search of Caribbean soul food

Caribbean cuisine is becoming increasingly popular in the UK ... and there's more to it than jerk chicken at carnival
11 best face powders

11 best face powders

Sweep away shiny skin with our pick of the best pressed and loose powder bases
England vs Norway: Roy Hodgson's hands tied by exploding top flight

Roy Hodgson's hands tied by exploding top flight

Lack of Englishmen at leading Premier League clubs leaves manager hamstrung
Angel Di Maria and Cristiano Ronaldo: A tale of two Manchester United No 7s

Di Maria and Ronaldo: A tale of two Manchester United No 7s

They both inherited the iconic shirt at Old Trafford, but the £59.7m new boy is joining a club in a very different state
Israel-Gaza conflict: No victory for Israel despite weeks of death and devastation

Robert Fisk: No victory for Israel despite weeks of devastation

Palestinians have won: they are still in Gaza, and Hamas is still there
Mary Beard writes character reference for Twitter troll who called her a 'slut'

Unlikely friends: Mary Beard and the troll who called her a ‘filthy old slut’

The Cambridge University classicist even wrote the student a character reference
America’s new apartheid: Prosperous white districts are choosing to break away from black cities and go it alone

America’s new apartheid

Prosperous white districts are choosing to break away from black cities and go it alone